320 related articles for article (PubMed ID: 7713475)
1. [Disorders of lipid metabolism in insulin resistance].
Müller-Wieland D; Krone W
Herz; 1995 Feb; 20(1):33-46. PubMed ID: 7713475
[TBL] [Abstract][Full Text] [Related]
2. [Dyslipoproteinemia and metabolic syndrome. Effects of insulin resistance and hyperinsulinemia on lipid metabolism].
Krone W; Müller-Wieland D; Wirth H
Fortschr Med; 1992 Dec; 110(34):645-8. PubMed ID: 1483617
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
6. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
7. Diabetic dyslipidaemia.
Erkelens DW
Eur Heart J; 1998 Jul; 19 Suppl H():H27-40. PubMed ID: 9717062
[TBL] [Abstract][Full Text] [Related]
8. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
McKenney JM
Pharmacotherapy; 1993; 13(4):340-52. PubMed ID: 8361860
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study.
Goff DC; D'Agostino RB; Haffner SM; Otvos JD
Metabolism; 2005 Feb; 54(2):264-70. PubMed ID: 15690322
[TBL] [Abstract][Full Text] [Related]
10. [The significance of insulin resistance and hyperlipidemia in microvascular angina (syndrome X)].
Langes K; Volk C; Schneider MA; Koschyk DH; Rinninger F; Nienaber CA
Z Kardiol; 1995 Mar; 84(3):180-9. PubMed ID: 7732710
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
12. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
15. Lipid and lipoprotein dysregulation in insulin resistant states.
Avramoglu RK; Basciano H; Adeli K
Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
[TBL] [Abstract][Full Text] [Related]
16. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
17. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
de Vries R; Borggreve SE; Dullaart RP
Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
[TBL] [Abstract][Full Text] [Related]
18. [Non-pharmacological therapy of metabolic syndrome].
Wirth A
Herz; 1995 Feb; 20(1):56-69. PubMed ID: 7713478
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia.
Xiao C; Watanabe T; Zhang Y; Trigatti B; Szeto L; Connelly PW; Marcovina S; Vaisar T; Heinecke JW; Lewis GF
Circ Res; 2008 Jul; 103(2):159-66. PubMed ID: 18556574
[TBL] [Abstract][Full Text] [Related]
20. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
